WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO, NUROW), today reported financial and business highlights for the quarter and nine month periods ended September 30, 2016.
The Company operates in two markets - wearable therapeutic technology and point-of-care diagnostic tests. The Company’s two primary products are Quell® and DPNCheck®. Quell is an over-the-counter wearable neurostimulation device for treating chronic pain that was launched in Q2 2015.
The Company operates in two markets - wearable therapeutic technology and point-of-care diagnostic tests. The Company’s two primary products are Quell® and DPNCheck®. Quell is an over-the-counter wearable neurostimulation device for treating chronic pain that was launched in Q2 2015.
